Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Reports Phase 3 Clinical Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Primary and Secondary endpoints met in MPS I Trial
- iPPS shows 3-year equivalent durability in OA Canine Study
- iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
- Phase 3 OA Trial to Proceed after Formal Safety Review
- PAR Receives Allowance for Key US Patent
Later from Paradigm Biopharmaceuticals
- 2023 Annual Report and Appendix 4E
- Ipps significant oa pain reduction at 12 months
- iPPS Increases Cartilage Thickness in Phase 2 Trial
- Paradigm Launches $30M Capital Raising
- Investor Presentation - $30m Capital Raise
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals